Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of PHVS is 46 and suggests 50% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase